Back

Different response of plaque regression under achieving LDL-C <1.8 mmol/L in non-obese and obese diabetic patients with coronary artery disease: a sub-analysis from the OPTIMAL randomized study

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Obesity (2) Obesity ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Anthony Salib

Austin Hospital, Melbourne (Australia)

5 More presentations in this session

Presentation thumbnail
Cardiovascular risk factors associated with normal weight obesity among Hispanic adults
Doctor A. Villarreal Rizzo (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Associations of visceral adipose tissue with ASCVD across BMI categories
Doctor U. Makhmudova (Berlin, DE) Doctor A. Sannino (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Impact of obesity on the association between salt intake and blood pressure in adults with hypertension: findings from cross-sectional and longitudinal analyses
Assistant Professor T. Adachi (Nagoya, JP)
Abstract Slides Video
Presentation thumbnail
Obesity duration and the risk of myocardial infarction: insights from the National Institutes of Health All of Us Research Program
Doctor S. Sidhu (New York, US)
Abstract Slides Video
Presentation thumbnail
Comparative effectiveness of sleeve gastrectomy and one-anastomosis gastric bypass on cardiovascular disease risk
Doctor D. Molavi zadeh (Tehran, IR)
Abstract Slides Video

Access the full session

Session thumbnail
Obesity (2)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Progressive disease substrate in obese type 2 diabetic patients with coronary artery disease despite achieving HbA1c <7.0%: sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
Body mass index as a contributor to the accumulation of lipidic plaque materials in statin-treated type 2 diabetic patients with coronary artery disease: sub-analysis from the OPTIMAL randomized study
thumbnail
Congress Presentation
High-intensity lipid-lowering therapy accelerates early plaque regression: a FLOWPROMOTE sub study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources